| Name | Title | Contact Details |
|---|
Medica HealthCare Plans is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Optics Institute of Southern California is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Federation of American Hospitals (FAH), founded in 1966, is the national representative of investor-owned or managed community hospitals and health systems throughout the United States and one of Washington, DC`s most respected and influential health policy and advocacy organizations. Dedicated to a market-based philosophy, we provide representation and advocacy on behalf of our members to Congress, the Executive Branch, the judiciary, media, academia, accrediting organizations and the public. The Federation of American Hospitals serves its members as a clearinghouse for information about the nation`s most vital health policy issues. These include Medicare and Medicaid, the uninsured, health care quality, patient safety, health information technology, medical liability insurance reform, rural health care, long-term hospital care, inpatient psychiatric care, hospital emergency preparedness, antitrust, compliance, the health care workforce shortage, privacy and confidentiality, tax issues, and rehabilitation services, among other important issues.
Suncoast Center is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.